The FDA has approved GlaxoSmithKline’s Jemperli (dostarlimab) immunotherapy, a drug acquired through its $5.1 billion acquisition of Tesaro, for certain patients with endometrial cancer.
Hosted on MSN8mon
Jemperli Cancer Drug: What To Know As GSK Says It Improves Survival For Uterine Cancer PatientsDostarlimab—known generically as Jemperli—was developed by GSK in partnership with the biotech firm AnaptysBio in 2014, as the company expanded into cancer drug sales. The drug was approved by ...
Hosted on MSN11mon
GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer StudyGSK plc (NYSE: GSK) announced headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial investigating Jemperli (dostarlimab ...
GSK says its PD-1 inhibitor Jemperli compared ... A 46% overall response rate (ORR) for Jemperli (dostarlimab) compared to 37% with Keytruda (pembrolizumab), both given alongside first-line ...
EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback